<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 7, 1996
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
NEW JERSEY 1-1-432 22-2429994
- --------------- ------------- ------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridan Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
-2-
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced today the election of
Dr. Zola P. Horovitz to its Board of Directors. The election of Dr. Horovitz
fills the vacancy created by the recent passing of W. Robert Fowler, M.D., a
long standing member of the Roberts Board.
Dr. Horovitz's career includes 35 years in senior management,
research and scientific positions with Bristol-Myers Squibb and The Squibb
Institute for Medical Research. He retired from Bristol-Myers Squibb in 1994.
Dr. Horovitz received the American Heart Association's Discovery Award for his
research leading to the development of the ACE inhibitor captopril and he is
also a recipient of the A.E. Bennett Neuropsychiatric Research Award for
original investigation in biological psychiatry. He received a PH.D. in
Pharmacology from the University of Pittsburgh and holds a Distinguished
Alumni Award from the University of Pittsburgh. Dr. Horovitz has published over
90 books, articles and abstracts. He is a fellow of the American Foundation for
Pharmaceutical Education and recently served as Commissioner of the New Jersey
Cancer Research Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: October 11, 1996 By: /s/ Anthony A. Rascio
-----------------------------
Anthony A. Rascio
Vice President
